Vibativ is a first in class dual-action bactericidal drug indicated in the treatment of nosocomial pneumonia caused by MRSA

Vibativ has a novel mechanism of action that could offer a lifeline to patients battling with antibiotic resistant infection. It has successfully achieved its primary endpoint of clinical response at follow up vs. Vancomycin patients with infection caused by Gram-positive bacteria 2



An executive summary of the efficacy of telavancin as assessed in the phase III ATTAIN studies - original publications available to download


Your suite of resources to explain the key benefits and evidence supporting the use of telavancin in patients with hospital-acquired pneumonia - presentations available to download